Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen, a France-based specialty pharmaceutical group, has reported that consolidated net profit was E147.2 million, or E1.75 per diluted share, for the full year 2008, a decrease of 2.2%, compared to E150.6 million, or E1.79 per diluted share, for the full year 2007.
Subscribe to our email newsletter
The company has reported total revenues of E1.04 billion for 2008, an increase of 4.5%, compared to E993.8 million for 2007.
Jean-Luc Belingard, chairman and CEO of Ipsen, said: “With revenues breaking above the E1 billion mark for the first time, sales growth of 8.2% year-on-year and a standalone operating margin of 21.6%, the group’s performance during 2008 was highly satisfactory and in line with the financial objectives set a year ago, in spite of the downturn in the economic environment.
“In a context of increased uncertainty, with all indicators suggesting that 2009 will be a tough year from a macroeconomic standpoint, the group remains confident in its ability to apply its strategy rigorously and pursue further expansion by harnessing its multiple sources of growth.”